SARS-CoV-2 in humans

被引:0
作者
Binder, Marco [1 ]
Wyler, Emanuel [2 ]
机构
[1] German Canc Res Ctr, Div Virus Associated Carcinogenesis, Res Grp Dynam Early Viral Infect & Innate Antivir, Heidelberg, Germany
[2] Max Delbruck Ctr Mol Med, Berlin Inst Med Syst Biol, Helmholtz Assoc, D-10115 Berlin, Germany
来源
BERLINER UND MUNCHENER TIERARZTLICHE WOCHENSCHRIFT | 2021年 / 134卷
关键词
SARS-CoV-2; COVID-19; molecular biology; transmission; epidemiology; pathogenesis; treatment; immunity; ATTACK RATE; AIRBORNE TRANSMISSION; COVID-19; INFECTION; REPLICATION; EVENTS; COHORT; ACE2;
D O I
10.2376/1439-0299-2020-28
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The novel coronavirus SARS-CoV-2 became pandemic at the beginning of 2020, and caused about 80 million cases and more than 1.8 million deaths by the end of the year. As its relatives MERS- and SARS-CoV, but in contrast to the four human coronaviruses circulating worldwide, SARS-CoV-2 in a sizeable fraction of cases leads to a severe and potentially life-threatening disease, called COVID-19. Since in addition this virus is very contagious, particularly prior to onset or in absence of symptoms, and pre-existing immunity appears to be largely absent or at least of very little relevance, it is spreading rapidly in the population. A hallmark of COVID-19 is an at least partially detrimental immune response that not only can lead to serious lung damage, but may also damage organs outside the respiratory tract such as the heart and kidneys. This review summarizes current knowledge about the virus and the disease it causes, and outlines open questions in the different research fields.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2
    Furuse, Yuki
    Oshitani, Hitoshi
    FRONTIERS IN MICROBIOLOGY, 2020, 11
  • [2] SARS-CoV-2 and hypertension
    Ravichandran, Briyanth
    Grimm, Daniela
    Krueger, Marcus
    Kopp, Sascha
    Infanger, Manfred
    Wehland, Markus
    PHYSIOLOGICAL REPORTS, 2021, 9 (11):
  • [3] SARS-CoV-2: pathogenesis, therapeutics, variants, and vaccines
    Li, Xi
    Mi, Ze
    Liu, Zhenguo
    Rong, Pengfei
    FRONTIERS IN MICROBIOLOGY, 2024, 15
  • [4] The adaptation of SARS-CoV-2 to humans
    Tosta, Eduardo
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2021, 116
  • [5] Is the kidney a target of SARS-CoV-2?
    Angel Martinez-Rojas, Miguel
    Vega-Vega, Olynka
    Bobadilla, Norma A.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2020, 318 (06) : F1454 - F1462
  • [6] SARS-CoV-2 and gastrointestinal diseases
    Sha, Ailong
    Liu, Yi
    Zhao, Xuewen
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [7] The panzootic potential of SARS-CoV-2
    Mabry, Makenzie E.
    Fanelli, Angela
    Mavian, Carla
    Lorusso, Alessio
    Manes, Costanza
    Soltis, Pamela S.
    Capua, Ilaria
    BIOSCIENCE, 2023, 73 (11) : 814 - 829
  • [8] Sequence similarity of SARS-CoV-2 and humans: Implications for SARS-CoV-2 detection
    Li, Heng
    Hong, Xiaoping
    Ding, Liping
    Meng, Shuhui
    Liao, Rui
    Jiang, Zhenyou
    Liu, Dongzhou
    FRONTIERS IN GENETICS, 2022, 13
  • [9] The Pathogenicity of MERS-CoV, SARS-CoV and SARS-CoV-2: A Comparative Overview
    Shashank, Patil M.
    Prithvi, Shirahatti S.
    Ramith, Ramu
    RESEARCH JOURNAL OF BIOTECHNOLOGY, 2021, 16 (01): : 182 - 192
  • [10] Mink, SARS-CoV-2, and the Human-Animal Interface
    Fenollar, Florence
    Mediannikov, Oleg
    Maurin, Max
    Devaux, Christian
    Colson, Philippe
    Levasseur, Anthony
    Fournier, Pierre-Edouard
    Raoult, Didier
    FRONTIERS IN MICROBIOLOGY, 2021, 12